Dostarlimab before colon surgery for mismatch-repair–deficient cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This study tests dostarlimab given before surgery for stage II or III colon cancer that has a specific DNA repair defect. It aims to shrink or control the cancer so that some people may be able to skip surgery if the results are good.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re 18 or older and can follow study instructions (or have a legal representative sign if mild cognitive issues).
- Your colon cancer is stage II or III and confirmed mismatch-repair deficient (dMMR) on biopsy tissue.
- Your tumor can be removed by standard surgery, unless the study team says it can be skipped based on outcomes.
- Scans within 28 days show no spread (no metastasis) to other parts of the body.
- Your blood counts and organ labs meet minimum levels (white blood cells, platelets, hemoglobin, kidney and liver tests).
- You can safely take the study medicine: no recent major surgery, no serious active infections/unstable heart problems, and no recent strong immune-suppressing treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests tislelizumab given after colon cancer surgery to lower the risk of the cancer coming back. It is for people with stage II or III colon cancer that has defective mismatch repair (dMMR).
This trial tests whether giving immunotherapy (pembrolizumab) before surgery can help treat stage I-III colon cancer that has a specific genetic feature (dMMR). The goal is to see if this approach can reduce the amount of surgery needed or improve outcomes.
This trial tests if the immunotherapy drug pembrolizumab can shrink colon cancers with specific genetic features (dMMR/MSI-H) before surgery. If the tumor responds well, some patients might avoid chemotherapy after surgery. It is for people with newly diagnosed, localized colon or upper rectal cancer.
This trial tests an investigational immunotherapy drug called dostarlimab given before surgery for colon cancer. It is for people whose tumor is MMR-proficient (also called MSS) and is large enough or has spread to nearby lymph nodes but not to other parts of the body. The goal is to see if this treatment can shrink the tumor before surgery.
This trial studies dostarlimab given around the time of colon cancer surgery for people with untreated, resectable (operable) stage T4N0 or stage III colon cancer that has specific tumor markers. It may help shrink or eliminate the cancer before or after surgery by boosting the immune response.
This Phase 2 trial studies dostarlimab (an immune therapy that targets PD-1) given before surgery or other initial treatment. It aims to shrink certain locally advanced cancers that have mismatch repair deficiency, potentially making treatment easier and improving outcomes.
Hear when a new Colon Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.